![]() SSc-associated ILD (SSc-ILD) is a mortality risk factor for patients with SSc 2. Interstitial lung disease (ILD) is a major complication and the leading cause of death in SSc, accounting for 35% of SSc-related deaths 1. Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by microangiopathy and fibrosis affecting the skin and visceral organs. The higher post-transplant survival rate at our institute than previously reported suggests that lung transplantation is acceptable in Asian patients with SSc-ILD. The 5-year survival rate for post-transplant patients with SSc-ILD was 86.2%. Analysis of 15 recipients showed improved forced vital capacity with a median of 55.1% at baseline, 65.8% at 6 months, and 80.3% at 12 months post-transplant. Median duration from registration to deceased-donor LT was 28.9 months and that from registration to living-donor LT or death was 6.5 months. Ten patients received deceased-donor LT (34%), two received living-donor LT (7%), seven died waiting for LT (24%), and ten survived on the waiting list (34%). We investigated post-transplant outcomes in recipients who underwent LT for SSc-ILD, between February 2002 and April 2022. In this single-center retrospective study, 29 patients with SSc-ILD, registered for deceased LT at Kyoto University Hospital, between 20, were identified. ![]() There is limited data on lung transplantation outcomes in patients with SSc-ILD, in non-Western populations.We assessed survival data of patients with SSc-ILD, on the lung transplant (LT) waiting list, and evaluated post-transplant outcomes in patients from an Asian LT center. ![]() Conclusion The continuous decrease of FT3 level and the continuous increase of FT4 and TSH levels are potentially associated with the poor prognosis of patients with hemorrhagic stroke, which is worthy of clinical attention.Advanced systemic sclerosis-associated interstitial lung disease (SSc-ILD) can be treated with lung transplantation. With the decrease of the patient's age, the serum FT3 level has a gradually increasing trend, and the serum FT4, TSH level, mortality and rebleeding rate have a gradually decreasing trend (P<0.05). The TSH level of the case group was significantly higher than that of the control group at all times (P0.05). The FT4 level of the case group was significantly higher than that of the control group at all times (P0.05). Results There were no statistically significant differences in gender and age between the three groups (P>0.05), but the differences in hypertension, hyperglycemia, and hyperlipidemia were statistically significant (P0.05). The epidemiological characteristics of patients with different prognosis and the dynamic change trend of FT3, FT4 and TSH in the same serum were compared. At the end of the follow-up, the subjects were divided into three groups death, rebleeding, and no adverse prognosis according to the prognostic outcome of the 12-month short-term follow-up. The assay method is enzyme-linked immunosorbent assay. Observe the trend characteristics of dynamic changes. Collect and analyze prognosis ( death, rebleeding, no adverse prognosis) at baseline and 12 months of follow-up monitor serum FT3, FT4, and TSH levels during treatment at the same time during follow-up, 7 days after treatment, and 14 days after treatment. ![]() Methods From January 2017 to January 2020, 227 patients with multicenter hemorrhagic stroke in our hospital were selected for analysis. Objective To discuss the epidemiological characteristics of the dynamic changes of serum FT3, FT4, and TSH levels in patients with hemorrhagic stroke under the age of 45, and to discuss the prognostic evaluation effects and influencing factors of these indicators. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |